Immunotherapy in breast cancer: A clinician's perspective.

J Natl Cancer Cent · 2021 · PMC11256727 · PMID 39035768

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Albeit not statistically different, this trial showed a trend towards worse OS in the atezolizumab arm (P+A= 22 months, P=28 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.